IA
EGRX

Icon Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Icon Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-41,000
Closed -$1.59M – 463
2016
Q2 		$1.59M Buy
+41,000
New +$1.71M 0.11% 215

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Icon Advisers's EGRX Position: Q3 2016 in Review

Icon Advisers sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2016, closing a stake of 41,000 shares — an estimated $1.59M sold.

Icon Advisers first reported a position in EGRX in Q2 2016 and held it in 1 quarter. The position peaked at $1.59M in Q2 2016. 137 funds tracked by Wall St. Rank hold EGRX as of Q3 2016.

  • Icon Advisers reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Icon Advisers sold 41,000 Eagle Pharmaceuticals, Inc. shares in Q3 2016, an estimated $1.59M.
  • Icon Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Icon Advisers's Eagle Pharmaceuticals, Inc. position peaked at $1.59M in Q2 2016.
  • 137 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2016.

Based on Icon Advisers's 13F filing for Q3 2016, filed 4 Nov 2016.